ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
Want to see ABVC full AI Analyst Report?
Total Valuation
ABVC BioPharma has a market cap or net worth of $28.60M. The enterprise value is $18.53M.
Market Cap$28.60M
Enterprise Value$18.53M
Share Statistics
ABVC BioPharma has 26,000,443 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,000,443
Owned by Insiders―
Owned by Institutions0.05%
Financial Efficiency
ABVC BioPharma’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -42.64%.
Return on Equity (ROE)-0.71
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-42.64%
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee0.00
Profits Per Employee-523.56K
Employee Count16
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ABVC BioPharma is ―. ABVC BioPharma’s PEG ratio is 0.88.
PE Ratio―
PS Ratio62.24
PB Ratio4.46
Price to Fair Value4.46
Price to FCF-16.56
Price to Operating Cash Flow-445.83
PEG Ratio0.88
Income Statement
In the last 12 months, ABVC BioPharma had revenue of 0.00 and earned -7.91M in profits. Earnings per share was -0.39.
Revenue0.00
Gross Profit0.00
Operating Income-7.15M
Pretax Income-8.35M
Net Income-7.91M
EBITDA-7.43M
Earnings Per Share (EPS)-0.39
Cash Flow
In the last 12 months, operating cash flow was -3.34M and capital expenditures 0.00, giving a free cash flow of -3.34M billion.
Operating Cash Flow-3.34M
Free Cash Flow-3.34M
Free Cash Flow per Share-0.13
Dividends & Yields
ABVC BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.61
52-Week Price Change-9.09%
50-Day Moving Average1.18
200-Day Moving Average2.15
Relative Strength Index (RSI)47.07
Average Volume (3m)95.05K
Important Dates
ABVC BioPharma upcoming earnings date is Nov 16, 2026, Before Open (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateNov 16, 2026
Ex-Dividend Date―
Financial Position
ABVC BioPharma as a current ratio of 0.41, with Debt / Equity ratio of 25.35%
Current Ratio0.41
Quick Ratio0.41
Debt to Market Cap0.07
Net Debt to EBITDA-0.42
Interest Coverage Ratio-17.20
Taxes
In the past 12 months, ABVC BioPharma has paid 24.15K in taxes.
Income Tax24.15K
Effective Tax Rate>-0.01
Enterprise Valuation
ABVC BioPharma EV to EBITDA ratio is -7.87, with an EV/FCF ratio of -17.49.
EV to Sales65.74
EV to EBITDA-7.87
EV to Free Cash Flow-17.49
EV to Operating Cash Flow-17.52
Balance Sheet
ABVC BioPharma has $202.51K in cash and marketable securities with $2.73M in debt, giving a net cash position of -$2.53M billion.
Cash & Marketable Securities$202.51K
Total Debt$2.73M
Net Cash-$2.53M
Net Cash Per Share-$0.10
Tangible Book Value Per Share$0.57
Margins
Gross margin is 0.00%, with operating margin of -898.46%, and net profit margin of -993.60%.
Gross Margin0.00%
Operating Margin-898.46%
Pretax Margin-1049.41%
Net Profit Margin-993.60%
EBITDA Margin-835.03%
EBIT Margin-898.46%
Analyst Forecast
The average price target for ABVC BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast-170.04%